Louisiana picks Gilead's generics unit for HCV subscription model

Louisiana has chosen to partner with Gilead's generics subsidiary to access a generic version of HCV drug Epclusa sofosbuvir/velpatasvir through a subscription-based model.

The state's Department of Health and Department of Corrections said the deal will provide unrestricted access for Medicaid and incarcerated patients for five years...